OT: INO Achieves Primary Endpoint in Phase II Cervical Trial

JHam
Administrator

Posts: 8,024

OT: INO Achieves Primary Endpoint in Phase II Cervical Trial Jul 23, 2014 17:19:49 GMT RLC likes this

Quote

Inovio (INO) is ONCS' biggest rival. Most feel (ONCS investors of course) that INO's technology is inferior to ONCS' and have long thought that if INO achieves positive data results that ONCS will as well. Anyway, here is the PR:

finance.yahoo.com/news/inovio-pharmaceuticals-hpv-immunotherapy-achieves-131500299.html

Last Edit: Jul 23, 2014 17:25:28 GMT by JHam

"There is no hair..."

JHam
Administrator

Posts: 8,024

OT: INO Achieves Primary Endpoint in Phase II Cervical Trial Jul 24, 2014 8:12:56 GMT

Quote

Ouch! INO filed an S-3 yesterday along with their positive data for 10.3M shares ($113M!) as an addition to the offering from a few days ago. Now totaling $175M.

I guess you have to take the good with the bad, lol.

www.sec.gov/Archives/edgar/data/1055726/000119312514277137/d742468ds3.htm

"There is no hair..."